Navigation Links
Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals, Inc. and Second Quarter 2009 Financial Results
Date:6/11/2009

d in Montreal, Canada and operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the results of clinical trials, impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.

Complete financial statements for the quarter ended April 30, 2009 are available on Haemacure's web site, www.haemacure.com, and have been filed on Sedar.

    Financial Highlights
    (unaudited)
                                                      Quarters ended

                                              April 30, 2009  April 30, 2008
                                              --------------  --------------

    Sales                                            $18,765         $28,368
    General and administrative expenses             $631,681      $1,327,551
    Research and development expenses               $581,164        $668,452
    Total expenses                                $1,252,377      $2,520,807
    Net loss                                     $(1,242,150)    $(2,504,982)
    Loss per share                                    $(0.01)  
'/>"/>
SOURCE HAEMACURE CORPORATION
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Haemacure and Angiotech Enter License, Distribution and Supply Agreements for Haemacures All-Human Fibrin Sealant and Thrombin Products
2. Haemacure Update on Proposed Collaboration and Bridge Financing
3. Haemacure Signs Term Sheet for Proposed Collaboration and Bridge Financing
4. Haemacure Reports First Quarter 2009 Results and Hires Advisor for the Sale or Merger of the Company
5. Haemacure Restructures - Seeks Financing or Sale of the Company
6. Haemacure to Present at the 11th Annual BIO CEO & Investor Conference
7. Haemacure Announces Fiscal 2008 Results
8. Haemacures Human Fibrin Sealant Demonstrates Effectiveness in Skin Graft Fixation Proof-of-Concept Study for Burn Injury
9. Haemacure Confirms Operation Qualification of Production Equipment and Pursues Milestone Payment from CSL
10. Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
11. Haemacure Appoints Thomas J. Lynch, J.D., Ph.D. to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Steven Reinberg HealthDay ... Pediatricians are urging that all children aged 6 months and ... American Academy of Pediatrics updated their influenza vaccine recommendations to ... of vaccine to build immunity. The AAP also wants parents ... kids the nasal spray vaccine instead of the flu shot ...
(Date:9/22/2014)... today became a founding partner in the Global STEM ... promoting young talent in science, technology, engineering and math ... York Academy of Sciences (NYAS), Malaysian Prime Minister Najib ... Sept. 22. , With the goal of developing over ... by 2020, the initiative will create a host of ...
(Date:9/22/2014)... 2014 This Flash Report is a ... needs for the Prostate Cancer market. , Download the ... strategies for any launching Prostate Cancer product:, ... an increasingly crowded market , Understanding stakeholder ... identifying community-based thought leaders and stakeholders ,Download the ...
(Date:9/22/2014)... London, UK (PRWEB) September 22, 2014 ... growth in the recent years. The statistically important data ... and safety of cancer vaccines. The primary challenge to ... sufficient information about the exact mechanism of how a ... leads to various results in different individuals owing to ...
(Date:9/22/2014)... -- Two new prescription devices approved by the U.S. ... for people with migraine headaches who don,t tolerate migraine ... device -- the Cefaly -- is designed to prevent ... is meant to be used when migraines first start, ... been looking for alternative migraine treatments. Because these devices ...
Breaking Medicine News(10 mins):Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:Growing scientists: World's future jobs are rooted in STEM 2Health News:Growing scientists: World's future jobs are rooted in STEM 3Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Noninvasive Devices May Help Migraines, FDA Says 2
... or two,have a significantly lower risk of having a ... epidemiologists at the University at Buffalo have shown. ... in the study who reported being,intoxicated at least once ... a heart attack than abstainers, results showed. ...
... authorities in Vietnam confirmed Wednesday the possibility that a resident ... have contracted the lethal H5N1 strain of the bird flu ... ,A fresh outbreak of bird flu has hit five ... H5N1 strain after being hospitalized in serious condition. ...
... drinking water, researchers said. ,There are strong grounds ... can reduce the risk of heart attacks. ... it is a wrong belief that tea leads to dehydration. ... antioxidants. It does not dehydrate you, Mirror quoted Ruxton, as ...
... that combination asthma therapy, SYMBICORT leads to significant ... greater patient-reported satisfaction with asthma treatment, versus ... ,SYMBICORT is a recently approved, combination therapy ... in patients 12 years of age and older. ...
... researcher at the Biodesign Institute at Arizona State University has ... stability and functions in comparison with the ones that occurred ... claims to have evolved several new proteins in a fraction ... ,The new findings have led to some surprisingly new ...
... researcher has revealed that fish possessed the genes associated with ... with limbs (tetrapods) came onto the scene about 365 ... in the Nature, Dr Marcus Davis said, the findings overturned ... was a novel evolutionary event and required the descendents of ...
Cached Medicine News:Health News:Moderate Drinking Lowers Women's Risk of Heart Attack 2Health News:Combo Therapy may Be Highly Beneficial in Asthma Control 2Health News:Genes Associated With Limb Development is More Primitive Than Believed 2
(Date:9/22/2014)... 22, 2014 Research and Markets  has ... Neurotechnology: 2014-2018" report to their offering. ... most comprehensive and up-to-date publication available covering the neurotechnology ... technology, markets, competitors, and growth rates in four key ... through 2018. It forecasts the number of systems to ...
(Date:9/22/2014)... Sept. 22, 2014 Research and Markets ... and Other Novel Hypercholesterolemia Drugs" report to their ... is a high cholesterol burden despite the presence of ... the available options, statins have been ubiquitously prescribed over ... of plasma LDL cholesterol (LDLC) is the cornerstone of ...
(Date:9/22/2014)... , September 22, 2014 Persistence ... on "Global Market Study on Ophthalmic Devices: ... the global ophthalmic devices market was valued at USD 29,171.5 million ... CAGR of 6.5% from 2014 to 2020, to reach ... Browse the full Global Market Study on Ophthalmic ...
Breaking Medicine Technology:The Market for Neurotechnology: 2014-2018 2PCSK9 and Other Novel Hypercholesterolemia Drugs 2PCSK9 and Other Novel Hypercholesterolemia Drugs 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5
... , COCKEYSVILLE, Maryland, November 2 ... Iron Phosphate Technology,to New Levels. , ... high-tech,batteries for industry, has expanded its range of lithium technologies ... phosphate,cell on the market. These large cells are designed for ...
... Shire plc (LSE: SHP, Nasdaq: SHPGY ... a major medical meeting from a Phase IIIb study of ... (methylphenidate transdermal system) in adolescents aged 13 to 17 years ... In addition, data regarding the pharmacokinetic profile of Daytrana in ...
Cached Medicine Technology:Saft Develops Super-Phosphate(TM) Technology for Rigorous Defense Applications 2Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 2Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 3Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 4Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 5Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 6Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 7
... of fibre bronchoscopy: The HF-compatible V series ... other fibre bronchoscopes are measured., ,The ... including the FB-19TV, FB-18V and FB-15V models ... the pediatric FB-8V, offer much better image ...
... High performance fiberoptic imaging from ... ,Olympus has improved its fiberscope range, ... specifications and enhanced image performance. Olympus ... instruments for diagnosis and therapy in ...
... performance fiberoptic imaging from the latest ... improved its fiberscope range, focussing on ... enhanced image performance. Olympus has a ... diagnosis and therapy in the respiratory ...
Slim bronchoscope designed for paediatric applications....
Medicine Products: